3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
6
Nivolumab
3
budigalimab
2
Paclitaxel
2
Ipilimumab
2
Docetaxel
2
venetoclax
1
tislelizumab
1
talazoparib
1
spartalizumab
1
rovalpituzumab tesirine
1
regorafenib
1
obinutuzumab
1
naptumomab estafenatox
1
fludarabine
1
epacadostat
1
durvalumab
1
cabozantinib
1
Platinum
1
Levoleucovorin
1
Leucovorin
1
Interleukin-2
1
IPI-549
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Everolimus
1
Cyclophosphamide
1
Clinical Trials, Phase II as Topic
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Blood Component Removal
×
Other solid neoplasm
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled